Benign Prostatic Hyperplasia Prostate Treatment Market Analysis

The global benign prostatic hyperplasia (BPH) prostate treatment market is segmented and analyzed for demand and supply by treatment type into drug, and surgical treatment. Out of these, the drug treatment segment is projected to witness noteworthy growth over the forecast period. The growth of the drug treatment segment is attributed to the rising consumption of drugs across the world. There are more than 20,000 prescription drugs approved in the United States for marketing. Also, about 70% of U.S. adults take prescription drugs. Also, the increment in sales of medicines from pharmacies is considered to be another growth factor for the segment. For instance, the sales of pharmacies and drug stores were projected to be around USD 300 billion in the USA in 2020.

Moreover, the global benign prostatic hyperplasia (BPH) prostate treatment market is further segmented by therapeutic class into BPH devices and BPH drugs. Out of these, the BPH drugs segment is predicted to hold the largest share over the forecast period. This can be attributed to the increased awareness related to the use of alpha blocker for relaxing the bladder neck, which helps the urine to flow in much easier manner. Benign prostatic hyperplasia treatment is the most general treatment for the men suffering with mild to moderate benign prostatic hyperplasia (BPH) prostate symptoms, and it is projected to surge the segment’s growth in the market.

.Our in-depth analysis of the global benign prostatic hyperplasia (BPH) prostate treatment market includes the following segments:

By Treatment Type

Drug Treatment
Surgical Treatment

By Therapeutic Class

BPH Devices

Transurethral RF Thermal Therapy
Suture Base Implant
Others

BPH Drugs

Alpha Blocker
Muscarinic Receptor Antagonist
5-Alpha Reductase Inhibitors

By Distribution Channel

Pharmacies
Online
Institutional Sales

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of benign prostatic hyperplasia prostate treatment is estimated at USD 8.22 billion.

The benign prostatic hyperplasia prostate treatment market size was over USD 7.86 billion in 2024 and is likely to cross USD 16.09 billion by the end of 2037, growing at more than 5.8% CAGR during the forecast period i.e., between 2025-2037. Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection will drive the market growth.

North America is projected to account for majority industry share by 2037, ascribed to rising geriatric population, an increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia.

The major players in the market include Pfizer Inc., Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc.

Benign Prostatic Hyperplasia Prostate Treatment Market Analysis